• Elysia Larson, Eran Bendavid, Maletela Tuoane-Nkhasi, Thobile Mbengashe, Thurma Goldman, Melinda Wilson, and Jeffrey D Klausner.
• American Schools of Public Health based at U.S. Centers for Disease Control and Prevention, Pretoria, South Africa elysia.larson@gmail.com.
• Int J STD AIDS. 2014 Aug 1; 25 (9): 636-42.

AbstractOur aim was to describe the association between increasing access to antiretroviral therapy and all-cause mortality in South Africa from 2005 to 2009. We undertook a longitudinal, population-level study, using antiretroviral monitoring data reported by PEPFAR implementing partners and province-level and national all-cause mortality records from Statistics South Africa (provider of official South African government statistics) to analyse the association between antiretroviral therapy and mortality. Using mixed effects models with a random intercept for province, we estimated the contemporaneous and lagging association between antiretroviral therapy and all-cause mortality in South Africa. We also conducted subgroup analyses and estimated the number of deaths averted. For each 100 HIV-infected individuals on antiretroviral therapy reported by PEPFAR implementing partners in South African treatment programmes, there was an associated 2.9 fewer deaths that year (95% CI: 1.5, 4.2) and 6.3 fewer deaths the following year (95% CI: 4.6, 8.0). The associated decrease in mortality the year after treatment reporting was seen in both adults and children, and men and women. Treatment provided from 2005 to 2008 was associated with 28,305 deaths averted from 2006 to 2009. The scale-up of antiretroviral therapy in South Africa was associated with a significant reduction in national all-cause mortality.© The Author(s) 2013 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

31 keywords...

hide…